Sort by
Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
Trofinetide US patent protections extended to March 2041
Pause in Trading
Update - Dividend/Distribution - NEU
Corporate Presentation, 2 September 2026
Dividend/Distribution - NEU
Investor presentation, 26 August 2026
Growing royalty anchors Neuren first ever dividend program
Half Yearly Report and Accounts
| Date | Headline |
|---|---|
5 Nov 2026 | Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded 2 |
2 Nov 2026 | FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE |
29 Sep 2026 | Trofinetide US patent protections extended to March 2041 1 |
29 Sep 2026 | Pause in Trading |
18 Sep 2026 | Update - Dividend/Distribution - NEU 1 |
2 Sep 2026 | Corporate Presentation, 2 September 2026 1 |
26 Aug 2026 | Dividend/Distribution - NEU 4 |
26 Aug 2026 | Investor presentation, 26 August 2026 |
26 Aug 2026 | Growing royalty anchors Neuren first ever dividend program 2 |
26 Aug 2026 | Half Yearly Report and Accounts |